Unprecedented OS with the addition of tarlatamab to first-line maintenance therapy for ES-SCLC

David Killock
Nature Reviews Clinical Oncology · Springer Nature · 2026-11-06 · DOI: 10.1038/s41571-026-01227-x

Abstract

Nature Reviews Clinical Oncology, Published online: 06 November 2026; doi:10.1038/s41571-026-01227-x Unprecedented OS with the addition of tarlatamab to first-line maintenance therapy for ES-SCLC

Read at publisher →

Similar articles